普萊柯(603566.SH):實控人張許科持股比例由33.47%變動至30.97%
格隆匯9月19日丨普萊柯(603566.SH)公佈,此次權益變動系普萊柯生物工程股份有限公司實施非公開發行A股股票方案,公司總股本由321,496,000股增加至352,916,573股,導致公司控股股東、實際控制人張許科持股比例被動稀釋超過1%,不觸及要約收購。
公司控股股東、實際控制人張許科參與此次非公開發行認購,認購股份1,679,496股,持有公司股份數量及比例發生變化。此次權益變動前,張許科持股數量107,619,672股,持股比例33.47%;此次權益變動後,張許科持股數量109,299,168股,持股比例30.97%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.